Recursion recently advanced REC-1245 into clinical trials, a drug candidate developed using the company's end-to-end workflow. Results from this program will be more meaningful, although trial results ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results